236 related articles for article (PubMed ID: 29214415)
1. A multi-center pragmatic, randomized, feasibility trial comparing standard of care schedules of filgrastim administration for primary febrile neutropenia prophylaxis in early-stage breast cancer.
Ibrahim MFK; Hilton J; Mazzarello S; Fergusson D; Hutton B; Robinson A; Califaretti N; Hsu T; Gertler S; Mates M; Stober C; Vandermeer L; Mallick R; Clemons M
Breast Cancer Res Treat; 2018 Apr; 168(2):371-379. PubMed ID: 29214415
[TBL] [Abstract][Full Text] [Related]
2. Feasibility of using a pragmatic trials model to compare two primary febrile neutropenia prophylaxis regimens (ciprofloxacin versus G-CSF) in patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer (REaCT-TC).
Clemons M; Mazzarello S; Hilton J; Joy A; Price-Hiller J; Zhu X; Verma S; Kehoe A; Ibrahim MF; Sienkiewicz M; Stober C; Vandermeer L; Hutton B; Mallick R; Fergusson D
Support Care Cancer; 2019 Apr; 27(4):1345-1354. PubMed ID: 30099602
[TBL] [Abstract][Full Text] [Related]
3. A multicentre, randomised trial comparing schedules of G-CSF (filgrastim) administration for primary prophylaxis of chemotherapy-induced febrile neutropenia in early stage breast cancer.
Clemons M; Fergusson D; Simos D; Mates M; Robinson A; Califaretti N; Zibdawi L; Bahl M; Raphael J; Ibrahim MFK; Fernandes R; Pitre L; Aseyev O; Stober C; Vandermeer L; Saunders D; Hutton B; Mallick R; Pond GR; Awan A; Hilton J
Ann Oncol; 2020 Jul; 31(7):951-957. PubMed ID: 32325257
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic pegfilgrastim to prevent febrile neutropenia among patients receiving biweekly (Q2W) chemotherapy regimens: a systematic review of efficacy, effectiveness and safety.
Mahtani R; Crawford J; Flannery SM; Lawrence T; Schenfeld J; Gawade PL
BMC Cancer; 2021 May; 21(1):621. PubMed ID: 34044798
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim in elderly versus non-elderly cancer patients: Patterns, outcomes, and determinants (MONITOR-GCSF study).
Aapro M; Bokemeyer C; Ludwig H; Gascón P; Boccadoro M; Denhaerynck K; Gorray M; Krendyukov A; MacDonald K; Abraham I
J Geriatr Oncol; 2017 Mar; 8(2):86-95. PubMed ID: 27829539
[TBL] [Abstract][Full Text] [Related]
6. A Comparison of Brand and Biosimilar Granulocyte-Colony Stimulating Factors for Prophylaxis of Chemotherapy-Induced Febrile Neutropenia.
Douglas AG; Schwab P; Lane D; Kennedy K; Slabaugh SL; Bowe A
J Manag Care Spec Pharm; 2017 Dec; 23(12):1221-1226. PubMed ID: 29172983
[TBL] [Abstract][Full Text] [Related]
7. A retrospective analysis of nadir-neutropenia directed pegylated granulocyte-colony stimulating factor on febrile neutropenia rates in (neo)adjuvant breast cancer chemotherapy regimens.
Zardawi SJ; Nordman I; Zdenkowski N
Cancer Rep (Hoboken); 2020 Oct; 3(5):e1266. PubMed ID: 32761893
[TBL] [Abstract][Full Text] [Related]
8. Febrile neutropenia (FN) and pegfilgrastim prophylaxis in breast cancer and non-Hodgkin's lymphoma patients receiving high (> 20%) FN-risk chemotherapy: results from a prospective observational study.
Salmon JP; Smakal M; Karanikiotis C; Wojtukiewicz MZ; Omnes Y; DeCosta L; Wetten S; O'Kelly J
Support Care Cancer; 2019 Apr; 27(4):1449-1457. PubMed ID: 30259136
[TBL] [Abstract][Full Text] [Related]
9. Comparison of filgrastim and pegfilgrastim to prevent neutropenia and maintain dose intensity of adjuvant chemotherapy in patients with breast cancer.
Kourlaba G; Dimopoulos MA; Pectasides D; Skarlos DV; Gogas H; Pentheroudakis G; Koutras A; Fountzilas G; Maniadakis N
Support Care Cancer; 2015 Jul; 23(7):2045-51. PubMed ID: 25524005
[TBL] [Abstract][Full Text] [Related]
10. Risk of chemotherapy-induced febrile neutropenia with same-day versus next-day pegfilgrastim prophylaxis among patients aged ≥65 years: a retrospective evaluation using Medicare claims.
Weycker D; Hanau A; Lonshteyn A; Bowers C; Bensink M; Garawin T; Chandler D
Curr Med Res Opin; 2018 Sep; 34(9):1705-1711. PubMed ID: 29962268
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF study.
Ludwig H; Bokemeyer C; Aapro M; Boccadoro M; Gascón P; Denhaerynck K; Krendyukov A; Abraham I; MacDonald K
Future Oncol; 2019 Mar; 15(8):897-907. PubMed ID: 30827127
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy.
Kahan Z; Grecea D; Smakal M; Tjulandin S; Bondarenko I; Perjesi L; Illes A; Horvat-Karajz K; Aradi I
BMC Cancer; 2019 Feb; 19(1):122. PubMed ID: 30727980
[TBL] [Abstract][Full Text] [Related]
13. Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice:a retrospective observational study.
Weycker D; Doroff R; Hanau A; Bowers C; Belani R; Chandler D; Lonshteyn A; Bensink M; Lyman GH
BMC Cancer; 2019 Aug; 19(1):792. PubMed ID: 31399079
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
Puértolas I; Frutos Pérez-Surio A; Alcácera MA; Andrés R; Salvador MDT
Eur J Clin Pharmacol; 2018 Mar; 74(3):315-321. PubMed ID: 29152672
[TBL] [Abstract][Full Text] [Related]
15. Filgrastim use in patients receiving chemotherapy for early-stage breast cancer-a survey of physicians and patients.
Hilton J; Vandermeer L; Sienkiewicz M; Mazzarello S; Hutton B; Stober C; Fergusson D; Blanchette P; Joy AA; Brianne Bota A; Clemons M
Support Care Cancer; 2018 Jul; 26(7):2323-2331. PubMed ID: 29411131
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of pegfilgrastim to support neoadjuvant dose-dense epirubicin and cyclophosphamide chemotherapy in breast cancer.
Wang X; He Y; Wang T; Xie Y; Li J; Ouyang T; Fan Z
Support Care Cancer; 2019 Aug; 27(8):3019-3025. PubMed ID: 30607682
[TBL] [Abstract][Full Text] [Related]
17. Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study).
Gascón P; Aapro M; Ludwig H; Bokemeyer C; Boccadoro M; Turner M; Denhaerynck K; MacDonald K; Abraham I
Support Care Cancer; 2016 Feb; 24(2):911-925. PubMed ID: 26306517
[TBL] [Abstract][Full Text] [Related]
18. A randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer.
Park KH; Lee S; Park JH; Kang SY; Kim HY; Park IH; Park YH; Im YH; Lee HJ; Park S; Lee SI; Jung KH; Kim YS; Seo JH
Support Care Cancer; 2017 Feb; 25(2):505-511. PubMed ID: 27709313
[TBL] [Abstract][Full Text] [Related]
19. Clinical Outcomes of Treatment with Filgrastim Versus a Filgrastim Biosimilar and Febrile Neutropenia-Associated Costs Among Patients with Nonmyeloid Cancer Undergoing Chemotherapy.
Schwartzberg LS; Lal LS; Balu S; Campbell K; Brekke L; DeLeon A; Elliott C; Korrer S
J Manag Care Spec Pharm; 2018 Oct; 24(10):976-984. PubMed ID: 29687743
[TBL] [Abstract][Full Text] [Related]
20. Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study.
Nahon S; Rastkhah M; Ben Abdelghani M; Soumoudronga RF; Gasnereau I; Labourey JL
Support Care Cancer; 2016 May; 24(5):1991-1998. PubMed ID: 26507190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
